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Abstract 
 
Introduction: 
           Menorrhagia is a common problem among females. It has many causes. 
It is common among patients with bleeding disorders and can be a presenting 
symptom.  
Objectives: 
           To assess the prevalence of bleeding disorders among women with 
menorrhagia  
Study design and procedure: 
This is a cross-sectional descriptive study, coducted in Khartoum 
Hospital (Dec2007-Feb2008); 34 women aged between 13 and 43 years presenting 
with menorrhagia were studied, where the usual gynecological and endocrinal 
causes of bleeding were ruled out by a gynaecologist. These patients were 
investigated for haemostatic defects by doing; platelet count and finger prick 
platelet aggregation test, bleeding time, prothrombin time, activated partial 
thromboplastin time, and when appropriate thrombin time and factor assay and 
factor XIII screening. Factor VIII level, vWf antigen, were done for all patients.  
Results and discussion:  
Of the 34 women investigated, 56% (19 cases) had a bleeding disorder to 
account for their menorrhagia. Although a majority of patients with platelet 
disorders and von Willebrand s disease (vWd), (47%) and (32%) respectively, 
other rare coagulation factor deficiencies such as factor V (10.5%), and factor X 
(10.5%) were also found.  Platelet disorders included count and function defects. 
History of bleeding from other sites, appeared as a significant finding, which 
might be used as a predictor for such a disorder in patients with menorrhagia. 
Family history of bleeding tendencies was not a predictive finding.  
 
 
                                                               
Conclusion and recommendations: 
 Patients with menorrhagia without a discernable cause, therefore, need 
evaluation for haemostatic disorders. This necessitate collaborate work between 
gynaecologists and haematologists, to exclude haemostatic abnormality. 
Especially before surgical intervention. vWd needs special consideration, since it 
might be missed by routine investigations. There should be a reliable, 
specialized laboratory in coagulation to reduce the discrepancy of results. 
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 Chapter One 
1. INTRODUCTION AND LITERATURE REVIEW    
1.1. INTRODUCTION:   
Menstruation is the monthly process by which the endometrium in 
fertile women is discarded if no pregnancy occurs. (1)  
A normal menstrual cycle is 21-35 days in duration, with bleeding lasting 
an average of 5 days and total blood flow between 25 and 80 ml. A blood loss of 
greater than 80 ml or lasting longer than 7 days constitutes menorrhagia (also 
called hypermenorrhea). In practice this is not usually directly measured by 
patients or doctors. Menorrhagia also occurs at predictable and normal (usually 
about 28 days) intervals, distinguishing it from menometrorrhagia, which occurs 
at irregular and more frequent intervals. It is possible to estimate the amount of 
bleeding by the number of tampons or pads a woman uses during her period. As 
a guide a regular tampon fully soaked will hold about 5ml of blood.(2)   
Menorrhagia is a very common complaint, affecting about 1 in 5 of all 
women of reproductive age. In the United Kingdom, for example, it accounts for 
about 12% of all patients referred to  gynecologists.(3)  Some people report its 
frequency as 30% of women in reproductive age. Recently, underlying bleeding 
disorders, particularly von willebrand’s disease and platelet dysfunction, have 
been found to be prevalent in women with menorrhagia.(3,4) The condition 
should always be diagnosed by a doctor to rule out a variety of potentially 
serious underlying conditions such as cancer and uterine fibroids.(5) 
Menorrhagia is a common symptom in patients with bleeding disorders. 
Studies have documented increased morbidity due to excessive bleeding in girls 
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and women. Women with bleeding disorders are more likely to be iron deficient 
and to have received blood transfusions. They are also more likely to undergo 
gynecologic surgical procedures and to have bleeding complications related to 
those and other surgical procedures. Furthermore, a number of studies have 
shown the effect of this excessive bleeding, particularly menorrhagia, on quality 
of life, including increased symptoms of depression, and increased days lost 
from work and social activity. Since menorrhagia in women with bleeding 
disorders frequently begins at menarche, these factors could have an impact on 
the social and academic development of the adolescent female.(3,6)  
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1 -2- Literature review: 
1-2-1- Defining the Problem: 
Menstrual problems may relate to the regularity, frequency or even the 
character of bleeding, but most commonly it is heavy periods, menorrhagia, 
which lead to a request for medical help. The problem of providing adequate 
health care for women with menorrhagia is immense as many women perceive 
their periods to be heavy, although, only some of them ever seek medical advice. 
Furthermore, even when a woman presents with the complaint of menorrhagia, 
the methods used to decide whether or not she has a clinical problem requiring 
treatment and any subsequent treatment options offered to her will be related to 
what is available from her healthcare provider and the availability of medical 
care as a fee-paying or government-provided service. Hence the management of 
menorrhagia varies enormously between cultures and between countries.(5) 
 
1-2-2 Pathophysiology of menorrhagia: 
Knowledge of normal menstrual function is imperative in understanding 
the etiologies of menorrhagia. Four phases constitute the menstrual cycle, 
follicular, luteal, implantation, and menstrual. In response to gonadotrophin-
releasing hormone (GnRH) from the hypothalamus, the pituitary gland 
synthesizes follicle stimulating hormone (FSH) and luteinizing hormone (LH), 
which induce the ovaries to produce estrogen and progesterone. During the 
follicular phase, estrogen stimulation results in an increase in endometrial 
thickness. This also is known as the proliferative phase. The luteal phase is 
intricately involved in the process of ovulation. During this phase, also known as 
the secretory phase, progesterone causes endometrial maturation. If fertilization 
occurs, the implantation phase is maintained. Without fertilization, estrogen and 
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progesterone withdrawal results in menstruation.(7) Without ovulation, the 
corpus luteum fails to form, resulting in no progesterone secretion. Unopposed 
estrogen allows the endometrium to proliferate and thicken. The endometrium 
finally outgrows its blood supply and degenerates. The end result is 
asynchronous breakdown of the endometrial lining at different levels. This also 
is why anovulatory bleeding is heavier than normal menstrual flow.(7) 
        The physiology and pathology of menstruation has been extensively 
studied; still several steps are not fully understood. A study supports a chain of 
events linking progesterone withdrawal to upregulation of the thrombin 
receptor, leading to an increased thrombin response and a release of edothelin, in 
turn leading to constriction in the coiled arteries. Thrombi are seen in the 
functional layers but are limited to the shedding surface of the tissue. These 
thrombi are known as "plugs" because blood can only partially flow past them. 
Fibrinolysis limits the fibrin deposits in the unshed layer. Following thrombin 
plug formation, vasoconstriction occurs and contributes to hemostasis.  The 
results also show that there is a high probability of revealing an earlier 
undiagnosed bleeding disorder when properly examining a woman with 
menorrhagia. Furthermore there was a significant correlation between the 
amount of menstrual blood loss and the fibrinolytic activity in the menstrual 
fluid both for women who bleed normally and for women with menorrhagia.(1)  
 
1-2-3- Causes of Menorrhagia: 
 Etiologies of menorrhagia are divided into 4 categories: organic, 
endocrinologic, anatomic, and iatrogenic.    
1-2-3-1 Organic causes of menorrhagia: include infection, bleeding disorders, 
and organ dysfunction. 
•  Infections can be of any genitourinary origin, sexually transmitted diseases 
are of greater concern. 
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•  Coagulation disorders can manifest as heavy menstrual bleeding, these 
include von Willebrand disease; coagulation factors deficiency; idiopathic 
thrombocytopenic purpura (ITP); and platelet dysfunction. (7) Hemostasis of 
the endometrium is directly related to the functions of platelets and fibrin. 
Deficiencies in either of these components results in menorrhagia.(1)  
• Organ dysfunction causing menorrhagia includes hepatic or renal failure. 
Chronic liver disease impairs production of clotting factors and reduces 
hormone metabolism (e.g., estrogen). Either of these problems may lead to 
heavy uterine bleeding. In patients with renal failure, gonadal resistance to 
hormones and hypothalamic-pituitary axis disturbances result in menstrual 
irregularities. Most women in this renal state are amenorrhoeic, but others 
also develop menorrhagia. If uremic coagulopathy ensues, it usually is due to 
platelet dysfunction and abnormal factor VIII function. The resulting 
prolonged bleeding time causes menorrhagia that can be very tenuous to 
treat.(7)  
 
1-2-3-2 Endocrine causes of menorrhagia: include thyroid and adrenal gland 
dysfunction, pituitary tumors, anovulatory cycles, polycystic ovary syndrome 
(PCOS), obesity, and vasculature imbalance. 
• Both hypothyroidism and hyperthyroidism result in menorrhagia. Even 
subclinical cases of hypothyroidism produce heavy uterine bleeding in 
20% of patients. Menorrhagia usually resolves with correction of the 
thyroid disorder. 
• Prolactin-producing pituitary tumors cause menorrhagia by disrupting 
(GnRH) secretion. This leads to decreased LH and FSH levels, which 
ultimately cause hypogonadism. Interim stages of menorrhagia result 
until hypogonadism manifests. 
• The most common etiology of heavy uterine bleeding is anovulatory 
cycles. The finding of menorrhagia at irregular intervals without any 
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known organic etiology confirms the clinical diagnosis. This is most 
common in adolescent and perimenopausal populations. 
• The hallmarks of PCOS are anovulation, irregular menses, obesity, and 
hirsutism. Insulin resistance is common and increases androgen 
production by the ovaries. 
• Hyperinsulinemia is a direct consequence of obesity. This overproduction 
of insulin leads to ovarian production of androgens, as occurs in PCOS. 
• Vasculature imbalance is theorized to be the result of a discrepancy 
between the vasoconstricting and aggregating actions of prostaglandin F2 
(alpha) and thromboxane A2  and the vasodilating actions of 
prostaglandin E2 and prostacyclin on the myometrial and endometrial 
vasculature.(7) 
1-2-3-3 Anatomic etiologies for menorrhagia: include uterine fibroids, 
endometrial polyps, endometrial hyperplasia, and pregnancy. 
 Fibroids and polyps are benign structures that distort the uterine wall and/or 
endometrium. Either may be located within the uterine lining, but fibroids may 
occur almost anywhere on the uterus. 
 Endometrial hyperplasia usually results from unopposed estrogen 
production, regardless of the etiology. Endometrial hyperplasia can lead to 
endometrial cancer in 1 -2% of patients with anovulatory bleeding, but it is a 
diagnosis of exclusion in postmenopausal bleeding. 
Anatomic defects or growths within the uterus can alter either of the 
aforementioned pathways (endocrinologic/haemostatic), causing significant 
uterine bleeding. The clinical presentation is dependent on the location and size 
of the gynecologic lesion. (7) 
1-2-3-4 latrogenic causes of menorrhagia: include (intra uterine contraceptive 
device) IUDs, steroid hormones, chemotherapy agents, and medications (e.g. 
anticoagulants). 
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• IUDs can cause increased menstrual bleeding and cramping due to local 
irritation effects. 
• Steroid hormones and chemotherapy agents disrupt the normal menstrual 
cycle, which is restored easily upon cessation of the products. 
• Anticoagulants decrease clotting factors needed to cease any abnormal 
blood flow, including menses. This type of menorrhagia also is easily 
reversible. 
 
Etiologic causes are numerous and often unknown. If the bleeding 
workup does not provide any clues to the etiology of the menorrhagia, a patient 
often is given the diagnosis of dysfunctional uterine bleeding (DUB). Most cases 
of DUB are secondary to anovulation. (7) 
Due to the overwhelming factors that can contribute to the dysfunction 
of either the endocrine or haematological pathways, in depth knowledge of an 
existing organic disease is just as imperative as understanding the menstrual 
cycle itself.(1,7) 
 
1-2-4- Diagnosis of Menorrhagia: 
The definition and diagnosis of heavy menstrual bleeding in women is 
tricky, because how one defines "heavy bleeding" is such a relative concept. Both 
the women's perception and the physician's perception of the importance of 
heavy menstrual-bleeding come into play. Since bleeding disorders tend to run 
in families, having a heavy menstrual flow may be considered normal in that 
family.(8) 
 
1-2-4-1- Measurement of menstrual loss 
One of the major problems confronting all clinicians is how to quantify 
the amount of menstrual loss which a woman experiences. The only available 
scientific method is the alkaline haematin method.(9)This is precise enough for 
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intensive clinical trials but has always been considered to be clinically 
impractical. Test samples of blood, either as liquid or soaked into sanitary 
napkins, vaginal tampons, or cotton pads are incubated at room temperature in 
5% (w/v) aqueous sodium hydroxide solution. After incubation, absorbance of 
the brown-colored alkaline haematin is measured at 550 nm in a 
spectrophotometer against a blank of either 5% sodium hydroxide or distilled 
water. The quantity of blood in each sample, represented by eluted, haematin-
converted hemoglobin, is determined from a standard curve relating various 
known volumes of incubated blood to absorbance at 550 nm (A550). Standard 
volumes of blood are always incubated for the same length of time as the 
samples. When the samples are diluted with more sodium hydroxide solution 
than the standards, sample absorbances are multiplied by an appropriate 
dilution factor. The photometric alkaline haematin procedure indicates a 
sensitivity to less than 0.1 ml of blood, and an accuracy of measuring human 
menstrual blood from most sanitary devices generally within plus or minus 5%. 
The method appears to be specific for menstrual blood and independent of other 
materials in genital fluids. Menstrual discharge could be stored for at least 1 
month prior to determination without alteration of results. maximum normal 
menstrual blood flow is between 60 and 80 ml, and the mean is near 30 ml. 
Variation of measured flow between consecutive menstrual cycles in some 
individuals (both normal and menorrhagic) reveals the necessity for repeated 
measurements to properly assess average blood flow in certain cases. (10) 
 Other simpler pictorial methods are available, which give a score for the 
amount of blood per sanitary pad, the nights with soiling, staining of clothes, 
and the total number of pads. But this method have not been adopted 
worldwide.(11) 
The majority of women have no experience of the quantity of other 
women's menstrual loss so they cannot make even a semi quantitative 
assessment with any reliability. The actual diagnosis of heavy menstrual loss is 
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usually based on the patient's history as interpreted by the gynecologist rather 
than any formal method of menstrual assessment.(12)(1) 
The patient who presents with such bleeding presents two distinct but 
important challenges for the clinician. The first is the exclusion of cancer or 
hyperplasia; the second is dealing with the annoyance as well as the fear that the 
bleeding engenders in the patient. Any attempt at appropriate therapy, whether 
surgical, hormonal or expectant, begins with an accurate diagnosis.        
Transvaginal ultrasound with saline infusion sonohysterography for selective 
patients has emerged as a safe, non-invasive, and inexpensive method of triaging 
patients with abnormal uterine bleeding in order to determine which patients 
require no further evaluation, blind endometrial sampling for a global 
endometrial process or visually directed endometrial sampling when pathology 
is thought to be focal.( 13) 
Specific investigations for a suspected cause of menorrhagia should be 
performed according to the clinical finding and clinical evaluation.(13) 
 
1-2-5 Bleeding disorders and menorrhagia: 
        As it has been mentioned, menorrhagia is a common problem among 
women of reproductive age. It is often a problem for women with inherited 
bleeding disorders.(6)  
          The United States US Centers for Disease Control and Prevention (CDC) 
program for women with bleeding disorders has included a series of 
collaborative research projects with the goals of establishing the prevalence of 
bleeding disorders; assessing physician awareness; improving diagnostic testing 
techniques; and evaluating treatment and management options. To better 
understand the population of women with bleeding disorders, CDC began by 
surveying 75 women with the most common bleeding disorder, von Willebrand 
disease (vWd), who were receiving care in hemophilia treatment centers (HTCs) 
across the United States. This internal survey addressed the origin of referral to 
 10
the HTC, symptoms experienced before diagnosis, diagnostic processes, services 
provided and perceptions of the HTC care.  Four findings were of particular 
interest: 86% of the women reported a long history of excessively heavy 
menstrual bleeding (menorrhagia), which was by far the most common 
symptom; it took an average of 16 years from the onset of symptoms until the 
woman learned she had vWd; more than half of the women had to be tested 
many times before receiving a diagnosis; and a large proportion of these women 
underwent surgical procedures, including hysterectomy, to alleviate the 
discomfort and effects of menorrhagia. In the survey, physicians were given a list 
of conditions, which included vWd, and were asked to rank each condition as a 
likely, uncertain or unlikely cause of menorrhagia. Only 3% of the responding 
physicians would consider vWd as a likely cause of menorrhagia in a woman 
aged 15 to 44. When asked the question "Given 1,000 women with menorrhagia, 
in your opinion, how many would be due to an inherited bleeding disorder," the 
answer, on average, was less than 1%. Although in practice an average of 20 
years, 42% of the responding physicians reported never having seen a woman 
with menorrhagia who had a bleeding disorder. Furthermore, the survey 
showed that gynecologists virtually never refer a woman with unexplained 
menorrhagia to another specialist.(14) Reports from Sweden and England 
indicated a higher prevalence of vWd and other bleeding disorders in women 
with menorrhagia (17% to 37%)(15,16) than perceived by the physicians in this 
survey. As a next step in the research agenda, CDC again collaborated with 
Emory University to perform an epidemiological study to determine the 
prevalence of bleeding disorders in a population of American women with 
menorrhagia in order to corroborate or refute the European findings. The study 
was conducted with women enrolled in a health maintenance organization 
during a specified time period. Participants were either of two groups: women 
with a diagnosis of menorrhagia according to the medical record or were among 
a random sample of women without the diagnosis who had seen a gynecologist 
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for other reasons. About half of the women in the study were African American. 
Laboratory testing performed at CDC showed that 8.2% of the women with 
menorrhagia had vWd or another clotting factor deficiency compared to 0.8% of 
the women without menorrhagia. To mimic the European studies, the diagnosis 
of vWd was examined separately for Caucasian and African American women. 
Significantly, vWd was found in 15.9% of white women with menorrhagia and in 
only 1.4% of African American women with menorrhagia. Two conclusions 
could be drawn from the findings of this study: 
First, the data supported the European studies indicating that the 
prevalence of vWd and other bleeding disorders in Caucasian women (about 
15%) was greater than the less than 1% perceived by gynecologists, and second, 
the prevalence of vWd may vary by race.(5)   
With sufficient epidemiological evidence of a high prevalence of 
bleeding disorders among women with menorrhagia, gynecologists face the 
dilemma of deciding which women should be tested for a bleeding disorder. 
Though, for the patient, coagulation testing entails only drawing a blood sample, 
the laboratory analysis is nevertheless expensive and must be performed by a 
laboratory experienced in coagulation. Along with the issue of who should be 
screened for bleeding disorders is a controversial list of how to screen. The CDC 
prevalence study revealed racial differences in vWd. With this discovery, CDC 
laboratory scientists examined coagulation factors in Caucasians and African 
Americans without bleeding disorders or other health problems. This research 
found baseline racial differences in several haemostatic parameters, specifically 
higher von Willebrand factor and factor VIII in African Americans compared to 
Caucasians.(6,17) Furthermore, preliminary data indicate that platelet disorders 
are more prevalent in African American women than in Caucasian women.(18) 
CDC is exploring the diagnostic and clinical implications of these racial 
differences. Another question in testing for vWd is whether to consider the 
menstrual cycle in determining when to test. Von Willebrand factor levels are 
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affected by estrogen. Underdiagnosis of vWd could result if raised estrogen 
levels, which occur at certain times during the menstrual cycle, give a falsely 
high reading of von Willebrand factor, thus causing a false negative test for vWd. 
Until recently, the consensus among hematologists has been to ignore the 
menstrual cycle when testing for vWd. However, recent data from CDC indicate 
that the lowest von Willebrand factor levels are on days one to four of the cycle 
(during menses) suggesting that this is the best time to test.(19) Laboratory 
research into new and better diagnostic procedures and techniques for women 
with bleeding disorders is ongoing at CDC and elsewhere. Until these new tests 
are developed, CDC encourages individuals who suspect a bleeding disorder to 
seek testing from laboratories experienced in coagulation in order to prevent the 
need for multiple tests to achieve an accurate diagnosis. 
The CDC research team on women with bleeding disorders recommends 
screening for vWd in adolescents with severe menorrhagia, adults with 
unexplained significant menorrhagia and before hysterectomy indicated for 
excessive menstrual bleeding.(20)(21) 
 The CDC undertook another survey of all obstetric/gynaecology in 
Georgia to ascertain the prevalence of menorrhagia among their patients and to 
determine the physicians' perceptions of bleeding disorders as a potential cause. 
Based on a 54 percent response rate, the survey indicated that about 8 percent of 
these physicians' patients experienced menorrhagia, but physicians rated 
bleeding disorders as the least likely cause for this problem. Indeed 42 percent of 
the responding physicians reported that they had never seen a patient with 
menorrhagia due to a bleeding disorder. This evidence clearly indicates a 
widespread lack of awareness of bleeding disorders in women among the 
obstetric/gynaecology providers.(21) 
 
 
 13
1-2-6 Women and Bleeding Disorders:  
There are several types of bleeding disorders that affect women. von
Willebrand disease (vWd) is the most common inherited bleeding disorder and
may affect up to 2.5 million American women. Women may also be
“symptomatic carriers” of hemophilia, meaning that in addition to carrying the
gene, they also exhibit symptoms similar to mild hemophilia. All of the rare
factor deficiencies, which include factor I, II, V, VII, X, XI and XIII, can also
result in bleeding among men and women. Platelets disorders and vascular
abnormalities are also recognized causes of bleeding. Aside from the fact that
women have similar symptoms to men with bleeding disorders, they can also
experience added obstetric and gynecological complications. vWd and other
bleeding disorders are particularly troublesome for reproductive-aged women.
Heavy and prolonged menstrual bleeding, can lead to serious complications if
left untreated. Other common symptoms include recurrent nosebleeds, easy
bruising, bleeding from the digestive or urinary tract and excessive bleeding
from the mouth or gums. 
Some doctors may not be familiar with bleeding disorders affecting
women, making a definitive diagnosis elusive. It is common for bleeding
symptoms to be attributed to other causes or to simply go unexplained. The
troubling aspect to this problem is that non-surgical treatments are available for
these conditions. In cases where a woman with a bleeding disorder (or
symptomatic carrier) becomes pregnant, she should see an obstetrician as soon
as possible. This will ensure that the doctor can consult with the local
hemophilia treatment center to provide pre- and postnatal care for the woman
and her baby. Decisions about what medical and surgical options to pursue
should be based on personal preference, family planning goals and severity of
bleeding problems.(22 ) 
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1-2-7 Pathophysiology of bleeding disorders:  
      The haemostatic system consists of platelets, coagulation factors, and 
the endothelial cells lining the blood vessels as well as the vessel wall. The body's 
reaction to vessel wall injury is rapid adhesion of platelet to subendothelium. 
The initial haemostatic plug, composed primarily of platelets, is stabilized 
further by a fibrin mesh generated in secondary haemostasis. The arrest of 
bleeding in a superficial wound, such as the bleeding time wound, almost 
exclusively results from the primary haemostatic plug. Platelet disorders lead to 
defects in primary haemostasis and have signs and symptoms different from 
coagulation factor deficiencies (disorders of secondary haemostasis).(23) 
 
1-2-7-1 Primary haemostasis: 
 The platelets arise from the cytoplasmic fragmentation of megakaryocytes 
in the bone marrow and circulate in blood as disk-shaped anucleate particles.  
Under normal circumstances, the resistance of the endothelial cell lining to 
interactions with platelets and coagulation factors prevents thrombosis. When 
endothelial continuity is disrupted and the underlying matrix is exposed, a 
coordinated series of events are set in motion to seal the defect (primary 
hemostasis). Platelets play a primary role in this process, interacting with 
subendothelium-bound von Willebrand factor (vWf) via the membrane 
glycoprotein Ib complex. This initial interaction (platelet adhesion) sets the stage 
for other adhesive reactions that allow the platelets to interact with each other to 
form an aggregate .  
The platelet glycoprotein (glycoprotein IIb/IIIa) complex mediates 
platelet-to-platelet interactions (platelet aggregation). On resting platelets, 
glycoprotein IIb/IIIa is unable to bind fibrinogen or vWf. Platelet activation 
allows binding of these proteins, which bridges adjacent platelets. 
Morphologically, the platelets change dramatically from disks to spiny spheres 
in a process called shape change.  
 15
Platelets contain two unique types of granules, the alpha granules and the 
dense granules. The alpha granules contain haemostatic proteins such as 
fibrinogen, vWf, and growth factors (e.g., platelet-derived growth factor). The 
dense granules contain proaggregatory factors such as adenosine 5'-diphosphate 
(ADP), calcium, and 5-hydroxytryptamine (serotonin). During activation, the 
granules are centralized and their contents are discharged into the lumen of the 
open canalicular system, from which they are then released to the exterior (the 
release reaction).  
Following activation, platelets have 2 major mechanisms to recruit 
additional platelets to the growing haemostatic plug. They release 
proaggregatory materials (e.g., ADP) by the release reaction, and they synthesize 
thromboxane A2 from arachidonic acid. Thus, the release reaction and 
prostaglandin synthesis act to consolidate the initial haemostatic plug by 
promoting the participation of other platelets in the growing haemostatic plug. 
In addition, when platelets are activated, negatively charged phospholipids 
move from the inner to the outer leaflet of the membrane bilayer. This negative 
surface provides binding sites for enzymes and cofactors of the coagulation 
system, resulting in the formation of a clot (secondary haemostasis).(23,24) 
 
1-2-7-2 Stabilization of the platelet plug by fibrin (secondary haemostasis): 
Definitive haemostasis is achieved when fibrin formed by blood 
coagulation is added to the platelet mass and by platelet induced clot 
retraction/compaction. 
Following vascular injury, the formation of excessive Xase (VIIa, TF, PL 
and Ca2+), and known as extrinsic pathway (fig1-1), is necessary and sufficient to 
initiates the coagulation cascade in vivo. Thrombin generated at the injury site 
converts soluble plasma fibrinogen into fibrin, potentiates platelet aggregation 
and secretion and also activates factor XI and XIII and cofactor V and VIII. The 
contact system (Intrinsic Pathway fig1-2 ) therefore does not appear to have a 
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physiological role in haemostasis.(24 )  Platelet aggregation and release reactions 
accelerate the coagulation process by providing abundant membrane 
phospholipid. The fibrin component of the haemostatic plug increases as the 
fused platelets autolyse and after few hours the entire haemostatic plug is 
transformed into solid mass of cross linked fibrin, factor XIII is responsible of 
crosslinking and stabilization of fibrin. In the final phase of normal hemostasis, 
fibrinolysis, the fibrin clot undergoes an orderly process of degradation. 
Deficiencies in the normal inhibitors of fibrinolysis, such as alpha 2-antiplasmin 
or plasminogen activator inhibitor-1, may be underdiagnosed causes of delayed 
bleeding because they are not identified by the usual coagulation screening 
tests.(23,24) 
Primary haemostatic disorders are characterized by prolonged bleeding 
time, and the characteristic physical examination findings are petechiae and 
purpura. In comparison, defects in secondary haemostasis exhibit delayed deep 
bleeding (e.g., muscles and joints) and the characteristic physical examination 
finding is Haemarthrosis. Haemarthrosis and muscle hematomas are not present 
in primary haemostatic disorders.(24 )  
Disorders of primary hemostasis, including thrombocytopenia and von 
Willebrand disease, are particularly important to consider when evaluating 
women with abnormal uterine bleeding. Patients with acquired or congenital 
deficiencies of either coagulation factors or the regulators of the fibrinolytic 
system may also present with menorrhagia. Accurate diagnosis of a bleeding 
disorder is essential to the design of an appropriate therapeutic regimen and is 
likely to have important clinical implications beyond that of the presenting 
gynecologic complaint.(23 )  
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Fig(1-1):Extrinsic pathway: 
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Fig(1-2) Intrinsic pathway: 
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1-2-8 Disorders of haemostasis: 
 
1-2-8-1 Hereditary coagulation factors disorders : 
1-2-8-1-1 Von Willebrand’s disease:  
von Willebrand’s disease is the most common inherited bleeding disorder. 
It is autosomal dominant, and its prevalence is estimated to be as high as 1 case 
per 1000 individuals.  
The hallmark of von Willebrand’s disease is defective platelet adhesion to 
subendothelial components caused by a deficiency of the plasma protein vWf. 
This factor is a large, multimeric protein synthesized, processed, and stored in 
the Weibel-Palade bodies of the endothelial cells, and it is secreted constitutively 
following stimulation. VWf has a major role in primary hemostasis as mediator 
of the initial shear-stress–induced interaction of the platelet to the 
subendothelium via the glycoprotein Ib complex. In addition, von Willebrand 
protein acts as a carrier and stabilizer of coagulation factor VIII by forming a 
complex in the circulation. In the absence of vWf, the factor VIII level is low. In 
classic hemophilia A, the factor VIII level is low because of a deficiency of factor 
VIII itself, whereas in von Willebrand disease, the factor VIII level is low because 
of a deficiency in its carrier protein. ( 24,25) 
von Willebrand disease is a relatively mild bleeding disorder, except in 
the occasional patient who is homozygous for the defect and who has severe 
bleeding often indistinguishable from classic hemophilia. The bleeding 
manifestations are predominantly skin-related and mucocutaneous (i.e., easy 
bruising, epistaxis, GI hemorrhage). Most bleeding episodes occur following 
trauma or surgery. In women, menorrhagia is common, often exacerbated by the 
concurrent administration of cyclooxygenase inhibitors. Pregnant patients with 
this disease usually do not have problems.  
 20
Bleeding time is prolonged in persons with von Willebrand disease. 
Because the von Willebrand protein is phase reactant (i.e., increased synthesis in 
the presence of inflammation, infection, tissue injury, and pregnancy), a mild 
prolonged bleeding time may be normalized, resulting in difficulty in diagnosis.  
In addition to the prolonged bleeding time, characteristic abnormalities in 
platelet aggregation tests occur. In patients with von Willebrand disease, 
platelets aggregate normally to all agonists except ristocetin. The antibiotic 
ristocetin induces binding of the von Willebrand protein to platelets, similar to 
what happens with platelets following vessel wall injury in vivo. Ristocetin-
induced platelet aggregation correlates with the platelet-aggregating activity of 
the von Willebrand protein. Levels of coagulation factor VIII are also low, 
resulting from a decrease in vWf. (24,25) 
 
Variants of von Willebrand disease:  
Von Willebrand disease results from either a quantitative or qualitative 
defect in von Willebrand factor (vWf ), a large multimeric protein which 
mediates platelet adhesion and serves as a carrier protein for factor VIII. 
There are three main types of von Willebrand disease. Type 1 is  
characterized by a partial deficiency of vWf antigen. It accounts for 70-80% of 
cases and is usually mild. Type 2 is caused by abnormalities in the von 
Willebrand protein leading to functional defect of the vWf protein. It consists of 
four subtypes based on their different pathophysiologic mechanisms (table 1-1). 
A common variant (type IIA) results from functionally defective vWf that is 
unable to form multimers. Larger multimers are more active in mediating 
platelet vessel-wall interaction. In these variants, the factor VIII level may be 
normal. In the type IIB variant, the von Willebrand protein has heightened 
interaction with platelets, even in the absence of stimulation. Platelets internalize 
these multimers, leading to a deficiency of von Willebrand protein in the plasma. 
Both types 1 and 2 are transmitted as an autosomal dominant trait. Type 3 is 
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characterized by a virtual absence of von Willebrand factor and is, therefore, 
typically severe. It is an autosomal recessive disorder and affected individuals 
are either homozygotes or compound heterozygotes.(23 )  
A disorder of platelet glycoprotein Ib has also been described. In this condition, 
increased affinity for von Willebrand protein in the resting stage leads to the 
depletion of plasma von Willebrand protein. This disease is called pseudo von 
Willebrand disease or platelet-type von Willebrand disease.  (23,24 )  
 
 
Table( 1-1 ) Subtypes of type 2 vWD: (24) 
Subtype     Platelet 
aggregation 
         Factor VIII binding 
capacity 
High MW 
vWf multimers 
2A Decreased Normal Abscent 
2B Increased 
affinity for GPIb 
Normal Usually 
reduced/ abscent 
2M Decreased Normal Normal or 
ultra large 
2N Normal Reduced Normal 
  
  
 
1-2-8-1-2 Haemophilia A and B: 
Haemophilias A and B result from deficiencies of coagulation factors VIII 
(FVIII) and IX (FIX), respectively. They are less common than von Willebrand 
disease but are the most common severe inherited bleeding disorders. They can 
cause significant morbidity and mortality through a spectrum of bleeding 
manifestations of various severities, for example, easy bruising, deep muscle and 
joint haemorrhage, spontaneous or post-surgery/post-traumatic bleeding and 
intracranial bleeding. Both are X-linked recessive disorders: men inherit the 
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condition and women are affected as carriers. Haemophilia A affects 1 in 5 000 , 
live male births and haemophilia B 1 in 30 000 live male births. Carriers of 
haemophilia usually have a clotting factor level around 50% of normal as they 
have only one affected chromosome. However, a wide range of values (22-116 
iu/dl) have been reported as a result of lyonisation (random inactivation of one 
of each pair of X chromosomes). Some haemophilia carriers have very low factor 
levels and are, therefore, at risk of severe bleeding complications.(23,26 ) 
 Carrier detection for haemophilia is based on four different methods:  
• Pedigree analysis, using the knowledge of X-linked recessive 
inheritance, to assess a woman's risk from her position in the family 
tree. Daughters of a man with haemophilia are obligate carriers. 
•  Phenotypic assessment based on assays of plasma FVIII, FIX and, 
in some cases, vWf. 
•  Direct gene mutation detection.  
• Indirect gene analysis involving the use of linked polymorphic 
markers to track heredity of a haemophilia gene within a pedigree 
when the mutation is not known.  
Direct gene analysis allows definitive diagnosis of carrier or non-carrier status 
while the other methods only ascertain risk of carriership of haemophilia. As 
20% of all people with haemophilia A and 50% of those with severe haemophilia 
have intron 22 inversion mutation, this is the starting point of direct mutation 
detection for severe cases. Mutation screening is performed in the remaining 
80%. When this not possible, linkage analysis is then undertaken.(23)  
 Preconceptual counseling: has two roles. The first is to provide women and their 
partners with adequate information on the genetic implications of their 
disorders, their reproductive choices and the management of their pregnancies, 
including options of prenatal diagnosis. This will assist them to reach a decision 
that is appropriate to their situation. Psychological support should be available 
during all aspects of counseling with an understanding of the ethnic and cultural 
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influences on each individual. The second is to allow planning for pregnancy and 
to perform a trial of desmopressin if appropriate. Other aspects of preconceptual 
care include immunization against hepatitis A and B for those likely to require 
blood transfusion and general advice, for example, regarding folic acid 
supplementation. (23) 
 
Table( 1-2 ):Clinical and laboratory findings in haemophilia A,B and 
vWd:( 24 ) 
 
 Haemophilia 
A 
Haemophilia B vWd 
 
Inheritance 
 
Main site of haemorrhage 
 
 
 
Platelet count 
Bleeding time 
Prothrombin time 
Partial thromboplastin time 
FactorVIII 
 
FactorIX 
VWF 
 
Ristocetin-induced platelet 
aggregation 
 
Sex linked 
 
Muscle, joint, 
post trauma 
or 
postoperative 
Normal 
Normal 
Normal 
Prolonged 
Low 
 
Normal 
Normal 
 
Normal 
 
Sex-linked 
 
Muscle, joint, 
post trauma or 
postoperative 
 
Normal 
Normal 
Normal 
Prolonged 
Normal 
 
Low 
Normal 
 
Normal 
 
 
dominant(incomplete) 
 
Mucous membranes, 
skin cuts, 
post-trauma or 
postoperative 
Normal 
Prolonged 
Normal 
Prolonged or normal 
May be moderately 
reduced 
Normal 
Low or abnormal 
function 
Impaired 
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1-2-8-1-3 Hereditary disorders of other coagulation factors: 
          All these disorders (deficiency of fibrinogen, prothrombin, factor V,VII, 
combined V and VIII, factors X,XI, XIII) are rare. In most the inheritance is 
autosomal recessive. They are much rarer than the haemophilias, they are 
expressed clinically only in homozygotes or compound heterozygotes. The 
underlying molecular defects and actual management of bleeding episodes are 
not well established as for haemophilia A and B. 
In countries where consanguineous marriages are frequent such as the Muslim 
world, recessively inherited coagulation deficiencies are more frequent and 
together reach prevalence higher than haemophilia B, representing a significant 
clinical and social problem. Their relative frequencies in the Islamic republic of 
Iran when compared with those registered in UK and Italy, are found to be three 
to seven times more frequent in Iran, except factor XI deficiency, because it is 
prevalent among Ashkenazi Jews, who are not common in that community.  (24 )  
          Autosomal recessively inherited coagulation deficiencies are generally less 
severe than haemophilias. The only exceptions are factor X and XIII deficiencies, 
characterized by the early onset of life threatening symptoms such as umbilical 
cord and central nervous system bleeding. Among the other disorders , a 
minority have spontaneous haemarthrosis and muscle haematomas. Mild 
bleeding symptoms such as epistaxis is very frequent among them. In 
afibrinogenaemia and factor V deficiency, this mucosal type bleeding may be 
explained by a concomitant defect of the protein in the patients’ platelets 
reflected by prolonged bleeding time, however no obvious explanation for the 
frequency of epistaxis and menorrhagia in defects of other factors such as 
prothrombin, factor VII and X. No evidence they cause reduced fertility or 
recurrent miscarriages, with the exception of factor XIII deficiency. Haematuria is 
also rare symptom except for factor X deficiency.(24)     
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1-2-8-2 Acquired coagulation disorders: (24) 
The acquired coagulation disorders are more common than the inherited 
disorders. Unlike the inherited disorders, multiple clotting factor deficiencies are 
usual.(23,24) they can occur in association with multisystem disease or 
pharmacological intervention. They may also occur at the extremes of age and in 
association with pregnancy. 
Below is a list of some of the causes of acquired coagulopathy:   
Deficiency of vitamin K-dependant factors: 
This can occur in a variety of conditions, e g, Biliary obstruction, 
malabsorption of vitamin K (e g. tropical sprue, gluten induced 
enteropathy),vitamin K antagonist therapy(e.g. coumarins, indandiones), 
antibiotic therapy and haemorrhagic disease of the newborn. 
Liver disease: 
Can cause deficiency of vitamin K dependant factors and other factors 
synthesized by the liver. 
Disseminated intravascular coagulation: 
Consumptive coagulopathy, low platelets count, and fibrin degradation 
products which interfere with coagulation and platelet function. 
Inhibition of coagulation 
           Specific inhibitors (e.g. antibodies against factor VIII) 
           Non specific inhibitors(e.g. antibodies found in anti phospholipid 
syndrome, systemic lupus erythematosus SLE, rheumatoid arthritis…etc.) 
Miscellaneous 
Therapy with heparin, defibrinating agents or thrombolytics 
Massive transfusion syndrome and cardio pulmonary bypass surgery. 
Alcoholism 
Diseases with M-protein production 
L-asparaginase 
Hypothermia 
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1-2-8-3 Disorders of platelet : 
Platelet defects can be considered either as a decreased number of 
platelets (thrombocytopenia) or as defective platelets. Platelet aggregation tests 
are useful in differentiating various disorders of platelet function. 
 
1-2-8-3-1Thrombocytopenia: 
It is a platelet count less than the reference range of normal (150-
400x109/l). Spurious thrombocytopenia can occur due to aggregates forming in 
the specimen. Also, dillutional thrombocytopenia may occur in situations of fluid 
replacement or blood component replacement without platelet support. In all 
cases of thrombocytopenia, the peripheral blood smear must be reviewed to 
confirm the thrombocytopenia. This review is crucial. 
Thrombocytopenia can be further divided into increased destruction or 
decreased production. Thrombocytopenia resulting from increased destruction 
occurs either by an immune mechanism(e g, autoimmune, alloimmune, drug-
induced), or increased consumption. Platelets are consumed intravascularly by 
the activation of the coagulation process (diffuse intravascular coagulation DIC) 
or by deposition on damaged endothelial cells (microangiopathy).  
 
          Production defects result from those diseases that cause bone marrow 
failure, such as aplastic anemia, isolated megakaryocytic aplasia, infiltration by 
leukemia or other malignancy, fibrosis or granulomatous disorders or 
tuberculosis; and other congenital and hereditary condition of 
thrombocytopenia. 
Functional disorders of platelets are relatively rare, and most of these 
disorders are mild and may not be recognized early in life. They can be inherited 
(rare) or acquired (common).(25 ) 
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1-2-8-3-2Disorders of platelet function:  
 Disorders of platelet function are as follows: 
 
Disorders of platelet adhesion (Bernard-Soulier syndrome) 
Disorders of aggregation (Glanzmann thrombasthenia) 
Disorders of secretion 
Disorders of thromboxane synthesis 
Acquired disorders of platelet function (drugs, eg, aspirin, NSAIDs, 
alcohol) 
Uremia 
Paraproteins 
Fibrin degradation products 
Myelodysplasia or a myeloproliferative syndrome.(24,25 ) 
 
1-2-8-3-2-1 Bernard-Soulier syndrome:  
This syndrome results from a deficiency of platelet glycoprotein protein 
Ib, which mediates the initial interaction of platelets to the subendothelial 
components via the von Willebrand protein. It is a rare but severe bleeding 
disorder. Platelets do not aggregate to ristocetin. The platelet count is low, but, 
characteristically, the platelets are large, often the size of red blood cells, and may 
be missed because most automatic counters do not count them as platelets. ( 25) 
 
1-2-8-3-2-2 Glanzmann thrombasthenia:  
This results from a deficiency of the glycoprotein IIb/IIIa complex. 
Platelets do not aggregate to any agents except ristocetin. Both Bernard-Soulier 
syndrome and Glanzmann thrombasthenia are characterized by life-long 
bleeding. Although platelet transfusions are effective, they should be used only 
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for severe bleeding and emergencies because alloantibodies often develop in 
these patients. (25 ) 
 
1-2-8-3-2-3 Disorders of secretion and thromboxane synthesis:  
During primary hemostasis, thromboxane synthesis and released ADP 
play a major role. A mild bleeding diathesis ensues if these mechanisms are 
deficient. Thromboxane synthesis disorders are almost always caused by aspirin 
and nonsteroidal anti-inflammatory drugs (NSAIDs).  
Mutations in the enzyme that converts arachidonic acid to thromboxane 
A2  have been described and are associated with a life-long bleeding diathesis. 
Similarly, an absent or defective receptor for thromboxane A2 also leads to an 
aspirin like aggregation defect. In disorders of release reaction, platelets fail to 
secrete proaggregatory ADP following activation. The defects result from either 
the absence of granules in platelets or the defective storage of ADP. ADP is 
present in the dense granules of platelets as a storage pool, which is not used in 
the normal metabolic activity of platelets (in contrast to the metabolic pool).  
Disorders of secretion and thromboxane synthesis are mild platelet 
disorders and often respond to desmopressin (DDAVP) infusion, which seems to 
improve haemostatic function. If severe bleeding is present, these disorders can 
also be managed effectively with platelet transfusions. Cryoprecipitate has also 
been reported to be very effective.(24,25 )  
 
1-2-8-3-2-4 Platelet dysfunction in uremia:  
Abnormal bleeding is common in patients with uremia. The bleeding has 
the characteristics of a platelet disorder, and GI tract bleeding is the most 
frequent symptom. Bleeding time is generally very prolonged in patients with 
uremia, signifying a major defect in platelet function, which improves after 
dialysis. A number of dialyzable platelet-inhibitory factors have been shown to 
inhibit platelet function. Furthermore, uremic platelets synthesize less 
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thromboxane A2, and the blood vessels taken from patients with uremia produce 
greater quantities of platelet-inhibitory prostaglandin. Nitric oxide produced by 
the endothelial cells inhibits platelet function. Because the prolonged bleeding 
time and the haemostatic abnormalities are partly corrected by red blood cell 
transfusion or erythropoietin therapy, the failure of hemoglobin to quench excess 
nitric oxide synthesis has been suggested as partly responsible for the platelet 
dysfunction. (25) 
 
1-2-8-4 Vascular disorders: 
                  The rare vascular disorders are a heterogeneous group of conditions 
characterized by easy bruising and spontaneous bleeding from small vessels. The 
underlying abnormality is either in the vessels themselves or in the perivascular 
connective tissues. 
Most cases of bleeding caused by vascular defects alone are not severe. 
Frequently, the bleeding is mainly in the skin causing petechiae, ecchymoses or 
both. In some disorders there is also bleeding from mucous membranes. In these 
conditions the standard screening tests are normal. The bleeding time is normal 
and other tests of haemostasis are also normal. Vascular defects may be inherited 
or acquired.(24 ) 
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1-2-9 Tests of haemostatic function: (24) 
A number of simple tests are employed to assess the platelet and coagulation 
components of haemostasis. 
• Blood count and blood film examination. 
• Screening tests of blood coagulation.(table1-3) 
• Specific assays of coagulation factors. 
• Bleeding time. 
• Tests of platelet function. 
• Test of fibrinolysis. 
 
 
 
Table(1-3) Screening tests used in the diagnosis of coagulation disorders: (24)   
 
Screening test Abnormality indicated by 
prolongation 
Most common cause of 
disorder 
Thrombin time(TT) Deficiency or abnormality of 
fibrinogen or inhibition of 
thrombin by heparin or FDPs 
DIC , Heparin therapy 
Prothrombin time(PT) Deficiency or inhibition of one 
or more of the following 
coagulation factors: VII, X, V, II, 
Fibrinogen. 
Liver disease  
Warfarin therapy 
DIC 
Activated partial 
thromboplastin time(APTT) 
Deficiency or inhibition of one 
or more of the following 
coagulation factors:XII, XI, IX, 
VIII, X, V, II, Fibrinogen.  
Haemophilia, Christmas 
disease,(+conditions above) 
Fibrinogen quantitation Fibrinogen deficiency DIC 
Liver disease 
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1-2-10 Management of menorrhagia in women with inherited 
bleeding disorders: 
A multidisciplinary approach is required for diagnosis and treatment. 
Gynaecological supervision is always required to exclude organic causes 
unmasked by the bleeding disorder. Treatment options are similar to those for 
menorrhagia in general with the addition of desmopressin and replacement 
therapy and the exclusion of non-steroidal anti-inflammatory drugs. The 
therapeutic plan should take into consideration the patient's preferences, age and 
severity of bleeding. Iron supplementation is of paramount importance. 
Remedies used in clinical practice for menorrhagia in general (tranexamic acid, 
combined oral contraceptives [COC], levonorgestrel intrauterine system [LNG-
IUS]) are first tried. In case of failure or contraindication (COC and LNG-IUS are 
best avoided in adolescents), before considering surgical options, treatment with 
desmopressin becomes the preferred choice in patients known to be responsive. 
The availability of desmopressin preparations for self-administration makes 
home treatment feasible in well selected cases. The treatment is efficacious and 
safe provided that patients are instructed to self-administer the agent only 
during the first two or three more heavy days of menstrual period, for a 
maximum of three to four doses and no more than two consecutive 
administrations at a 12-h interval.(27,28 )plasma or factor replacement may be 
needed in some cases. 
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1-3 Justifications 
 
Menorrhagia is a very annoying problem. It can seriously affects 
women's quality of life in different ways, for example; many women limit the 
amount of time they work or change careers as a result of bleeding problems, 
many women are unable to work normally during their menstrual periods, many 
women have lost faith in the medical profession after being told for years their 
problems were not real, they might suffer constant fatigue from iron deficiency 
anemia, some women suffer from depression as a result of the stress of their 
bleeding disorder, many women suffer pain during their menstrual periods and 
times of ovulation, many girls and women must live with the embarrassment of 
staining due to heavy bleeding. Adolescents in particular would face the 
psychological trauma of the frightening sight of excessive bleeding, which could 
be their first experience with menstruation. Many women have had 
hysterectomies, their bleeding symptoms were ignored and doctors could not 
diagnose their bleeding disorder, this means they could not have any more 
children(15).   
Menorrhagia is a common complaint in the gynaecology departments as  
observed by many doctors in practice, yet there is no objective informations 
about how frequent is it in Sudan. Many patients may not show an obvious 
cause, gynaecologist may suffer searching for the aetiology of such a disorder, 
many times symptomatic and blind treatment is offered to them. Many patients 
with known bleeding disorder, suffer from excessive menstruation.(3) 
Considering haemostatic abnormalities as a possible cause of 
menorrhagia, this study was carried out to assess the prevalence of bleeding 
disorders among females presenting with menorrhagia in Khartoum hospital. 
This is the first study to deal with this issue in Sudan. 
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1 -4 Objectives: 
 
1-4-1 Major objectives: 
• To assess the prevalence of bleeding disorders among women 
presenting with menorrhagia.  
• Classification of the types of bleeding disorders among the study 
population.  
 
1-4-2 Minor objectives:  
• To measure the bleeding time, prothrombin time and activated 
partial thromboplastin time of the study population. 
• To do other factors assay when coagulation abnormality is 
suspected.  
•  To screen for factor XIII deficiency when other screening tests are 
normal. 
• To do platelet count and finger prick platelet aggregation. 
• To measure the level of von willebrand’s factor antigen and  factor 
VIII assay for all the study population. 
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Chapter Two 
2. METHODOLOGY  
 
  
2-1- Study design: 
This is a cross-sectional descriptive study from December 2007 to 
February 2008. 
 
2-1-2- Study area: 
The study was conducted in the Obstetrics and Gynaecology Referred 
Clinic (Fath Alrahman Albashir), and haemophilia unit, Khartoum Teaching 
Hospital.  
 
2-1-3- Study population: 
Females in the reproductive age presenting to Khartoum Teaching 
Hospital, complaining of menorrhagia. Which was confirmed by a gynaecologist. 
 
2-1-3-1 Inclusion criteria: 
Any female in the reproductive age, with gynaecologist diagnosis of 
menorrhagia, and normal ultrasonography and hormonal assay. 
 
2-1-3-2 Exclusion criteria: 
With exclusion of: 
• known cases of bleeding disorders. 
• gynecological malignancy or fibroid. 
• use of intra uterine device. 
• liver disease and renal disease. 
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• Use of anticoagulants within the last 2months. 
• use of nonsteroidal anti inflammatory agents, e g Aspirin and anti 
platelets drugs within 14 days of participation. 
 2-1-4  Ethical consideration: 
A verbal consent was taken after being informed by all details of the 
objectives of the study, and its health emphasis in the future. 
 
2-2 Data collection: 
 
2-2-1 Pre coded questionnaire (appendix 1): 
A questionnaire was specifically designed to obtain informations about 
the demographic data of the study population, as well as bleeding history and 
family history.  
Some of the data was obtained from records of patients investigated 
within the haemophilia unit, who presented with menorrhagia as a chief 
complaint, and had no previous diagnosis of bleeding disorder.           
 
2-2-2 Investigations: 
Preliminary screening was done: bleeding time, prothrombin time and 
partial thromboplastin time; as well as platelet count and finger prick platelet 
aggregation. when  any coagulation abnormality was found, further tests and 
appropriate factor assay  was performed. Von Willebrand antigen and factor VIII 
level were done for all patients. Factor XIII assay was done when no other 
abnormality was found.   
 
 
2-2-2-1 Equipment: 
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1. Syringes. 
2. Containers with anti coagulant: EDTA and Tri Sodium Citrate. 
3. Lancets. 
4. Filter paper. 
5. Alcohol swabs and cotton gauze. 
6. Centrifuge capable of generating at least 1700 g. 
7.  Temperature-controlled waterbath maintaining temperatures of 37°C 
± 1°C. 
8. Stopwatches. 
9.  Automatic adjustable pipettes in the range of (0 -200 µl) and up to 
1000 µl. 
10. Calibrated pipette for delivery of liquid volumes up to 5 ml.  
11. Test tubes. 
12.  Glass slides. 
13.  Coagulometer (BIOPASS ):  
            Principle of action:  
                        It acts by mechanical detection based on ball method. It 
measures the time from addition of the starter reagent to the onset of in 
vitro clot formation. The sample is located in the cuvette inclined at an 
angle, which is slowly turned about its longitudinal axis. A surface treated 
steel ball is located at the bottom of the cuvette by means of gravity. The 
time measurement starts with the addition of the starter reagent. At the 
onset of coagulation the fibrin clot pulls the ball along. The positional 
change of the ball triggers an impulse in a magnetic sensor which 
electronically stops the timer. 
14.  Other additional equipment is required for some procedures 
including: A microtitre plate reader for enzyme-linked immunosorbent 
techniques (ELISA). 
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2-2-2-2 Materials: 
Reagents used will be mentioned with each method. 
2-2-2-3 samples collection and preparation: 
After cleaning with alcohol swab, five milliliters of venous blood were 
collected from the antecubital fossa of sitting patients-using a disposable 5 mls 
syringe. 2.25 mls was drawn immediately into a container containing 0.25 mls of 
13.3g/l aqueous tri sodium citrate (9 parts of freshly collected blood to one part 
of tri sodium citrate). The other 2.5 mls were delivered into a container with 
EDTA (Ethylenediamine tetra acetic acid) anticoagulant. Both containers were 
then mixed well and gently and taken to the laboratory for analysis within two 
hours. 
EDTA sample was used for platelet count measurement; citrated sample 
for preparation of platelet poor plasma (ppp). A platelet poor plasma was 
obtained by centrifugation at 2500g for 15 minutes. Then used for coagulation 
testing; PT, aPTT and TT (when needed). The rest of (PPP) was frozen at -200c for 
further testing; VWf ag, factor XIII screening, and specific factor assay if 
indicated.              
 
2-2-3 Methods of estimation: 
 
2-2-3-1 Bleeding time: (Duke Method) 
The ear lobe was cleaned and warmed, a sharp sterile lancet was used to 
make a prick in the earlobe, timer was stated as soon as the first drop of blood 
appeared. Filter paper was used to plot the drop of blood every 15 seconds. The 
bleeding time was recorded when the bleeding stopped. Normal range 
(<7min)(29). 
 
 
2-2-3-2 Finger prick platelet aggregation: 
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This is a simple procedure to assess the ability of the platelet to form an 
aggregate. 
Procedure: 
The middle finger was cleaned and dried. Using a lancet, the finger was 
pricked. A drop of blood was placed on three slides 30 seconds apart; blood 
smear was made; stained by Leishmain stain and examined under the 
microscope. 
Platelet aggregates were expected to be found in the second and third 
slide indicating normal platelet function. 
 
2-2-3-3 Platelet count:  
The EDTA anticoagulated blood sample (above) was used for platelet 
count determination. Sysmex automated hematology analyzer KX-21N was used. 
reference range (150 ×109/l – 400 ×109/l) (29 ). 
 
2-2-3-4 Prothrombin time PT( appendix 2): 
 Sample: 
  platelet poor plasma (ppp). 
Principle:                                                   
This test reflects the overall efficiency of the extrinsic system. It is sensitive 
to changes in factor V, VII and X, and less so to factor II (prothrombin). It is also 
unsuitable for detecting minor changes in fibrinogen level, but may be abnormal 
if the fibrinogen level is very low or if there is an inhibitor present. The 
sensitivity of the test is influenced by the reagent and technique used and it is 
important to establish a reference range locally. 
 
 Equipment: 
•  Stopwatch. 
•  Pipettes. 
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• Water bath. 
•  Coagulometer: its principle of action is mentioned earlier.   
 Reagents: 
Thromboplastin (which contains calcium chloride), purchased from 
DiaMed AG ( appendix) 
 
 procedure: 
1. After switching on the coagulometer, the cuvettes were placed in the 
unheated preparation area. pre warming of the reagent was done. 
2. The steel peads were dispensed into the cuvettes. 
3. 0.1 ml of the commercial control plasma and patient plasma were 
pipetted , each one in a separate cuvette. Then they were placed in the 
rotating test area and incubated at 37c for 3 minutes. 
4. Then timer was started by adding the 0.2 ml of PT reagent. 
5. The results were recorded in seconds. (Each test was done in 
dublicate). 
6. Reference range was taken as 11-14.(30) 
 
2-2-3-5 Activated partial thromboplastin time (APTT)(appendix 3): 
 Principle:                                                      
This is a non-specific test of the intrinsic system. Taken together with a 
normal prothrombin time, it is the most useful screening test for detecting 
deficiencies of factors VIII, IX, XI and XII. 
The APTT will also be prolonged in any deficiency involving the common 
pathways (deficiencies of factors V, X, II and to a lesser extent fibrinogen) and in 
the presence of inhibitors. The presence of some therapeutic inhibitors of 
coagulation, such as heparin, will also prolong APTT. It is important to rule out 
these treatments as a cause of prolonged APTTs before continuing with other 
tests.  
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 Equipments: 
• Pipettes. 
• Stopwatches. 
• Coagulometer.  
 Reagents: 
• APTT reagent (purchased from DiaMed AG  (appendix). 
 
 Procedure: 
1. The cuvettes were placed in the unheated preparation area. pre 
warming of the reagent was done. 
2.  The steel peads were dispensed into the cuvettes. 
3.  0.1 ml of the commercial control plasma and patient plasma were 
pipette, each one in a separate cuvette. Then they were placed in the 
rotating test area.  
4. 0.1 ml of the PTT reagent was added and incubated at 37°C. After 3 
minutes, 0.1 ml of calcium chloride was added and the timer started. 
5.  The reading of the coagulometer was recorded in seconds. 
6. Reference range was taken as (23-33)seconds. 
 
2-2-3-6 Thrombin clotting time (TT): 
Principle: 
The thrombin time reflects the reaction between thrombin and fibrinogen. 
Thrombin 
Fibrinogen Fibrin 
It is prolonged when the fibrinogen level is very low, in the presence of 
heparin and heparin-like substances, in the presence of other inhibitors, e.g. 
fibrin(ogen) degradation products (FDPs) and 
when fibrinogen is qualitatively1 abnormal (dysfibrinogenaemia). 
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Equipment: 
• Test tubes 
• Stopwatches 
• Pipettes 
• waterbath 
Reagents (DiaMed): 
• Thrombin solution which induces clotting of normal plasma in about 15 
seconds 
• Control plasma 
Method: 
1. 0.2 ml test and control plasma  were Pipetted into separate cuvettes. 
2. Warmed to 370 C. 
3. 0.2 ml thrombin added to each tube. Timer started and clotting time was 
recorded for each tube. 
referance range: (15-19 seconds)(29 ) 
4. Test was done in duplicate. 
Results/Interpretation 
  
The thrombin reagent used  gave a clotting time of around 15 seconds 
with control normal plasma. 
 
2-2-3-7  Further investigation of abnormal PT and APTT: 
Principle: 
Plasma samples found to have abnormal screening tests, i.e. PT/APTT, 
were further investigated to determine the cause of the abnormality. Knowing 
the principle that abnormal PT or PTT will be corrected ,if mixed (50:50) with 
normal plasma, by more than 50% of the difference between the clotting times of 
the normal and test plasma, and hence factor deficiency is indicated. And when  
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the test plasma is mixed (50:50) with plasma of known coagulation factor 
deficiency, the level of the deficient factor is then determined. 
 
2-2-3-7-1 Factor assay:(Appendix 4) 
A reduction of single factor activity can be determined by carrying out a 
one stage test ( thromboplastin time PT, or partial thromboplastin time PTT) with 
known factor deficient plasmas. The principle of this test rests on the fact that, all 
the other factors necessary for coagulation are present in sufficient quantities in 
the deficient plasma. The factor deficiency can be quantified as a percentage by 
using a calibration curve. 
Reagents: 
1. Factor deficient plasma. 
2. Owren’s Veronal Buffer, PH 7.35. 
3. PT or PTT reagens. 
Procedure:  
Following the procedure mentioned in the KIT (appendix); fresh normal plasma 
(PPP) was used to set a calibration curve. Double dilution starting with 1/10 (as 
the 100% activity) was  made; PT or PTT was done for each dilution ; and reading 
plotted on a double log paper.  
The test plasma was treated the same; after mixing with deficient plasma. 
the reading of 1/10 dilution was taken from the curve as the value of the factor 
activity of the test plasma. 
 
*NB!: Poor correction of the 50:50 mix of test plasma with normal plasma, 
suggests an inhibitor, possibly to one of the clotting factors in the system or of 
the non-specific type, such as lupus anticoagulant.  
When they are suspected, inhibitors of specific coagulation factor may not 
appear at zero time, and correction of the initial mix should not be interpreted 
until the incubation time is completed.   
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2-2-3-9 factor XIII screen: 
Principle 
Thrombin and calcium (Ca2+) are required to activate FXIII so that it will 
crosslink fibrin into a stable form. In this method, despite using citrated plasma, 
sufficient Ca2+ ions are still available for XIII activation. A normal ethylene 
diamine tetracetic acid (EDTA) anticoagulated plasma is used for a control. In 
this plasma, EDTA chelates  the calcium ions completely, which means that the 
factor XIII is not able to crosslink fibrin. Addition of 2% acetic acid or 5 M urea 
results in the lysis of non-crosslinked clots. Citrated plasma with greater than 10 
u/dl of FXIII activity has an insoluble clot. 
Equipments: 
• 75 × 10 mm glass tubes. 
•  Stoppers 
Reagents: 
•  0.9% saline. 
•  30 u/ml thrombin. 
•  Normal EDTA plasma.  
• Urea.  
Method: 
1. 0.2 ml citrated test plasma was added to 0.2 ml 0.9% saline in glass tube.  
Repeated with 0.2 ml EDTA normal plasma, for a negative control, and 
repeated with 0.2 ml normal citrated plasma, for a positive control. 
2.  To each tube 0.1 ml of 30 u/ml thrombin was added and mixed. 
3.  Then the tubes were Left for 30 minutes at 37°C.  
4. Flicking the tubes to loosen clot from side of tube. 
5. 5 ml of 5 M urea was added to each tube and stopperd. then tubes were 
left at room temperature overnight. 
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Results/Interpretation: 
EDTA plasma should have no visible clot. 
Normal citrated plasma should have an intact clot visible. 
If a clot is not visible in the test plasma, the subject has factor XIII 
deficiency. 
Normal range: 
Normal subjects have visible clot after overnight incubation. 
 
 
2-2-3-10 Von Willebrand antigen assay:( (Appendix5) 
Antigenic assay for the quantitative determination of von Willebrand 
factor by the enzyme linked immunosorbent assay (ELISA). 
 
Principle:   
The vWf to be measured by specific rabbit anti-human vWf antibodies 
coated on the internal walls of  a plastic microplate well. Next, rabbit anti-vWf 
antibodies coupled with peroxidase bind to the remaining free antigenic 
determinants of vWf. The bound enzyme peroxidase is revealed by its action on 
the on the tetramethyl benzidine (TMB) substrate.  
 After stopping the reaction with strong acid the intensity of the color is 
directly proportional to the concentration of vWf initially present in the sample. 
 
 Samples:  
         platelet poor plasma which was stored at -200c. Assayed as a patch analysis. 
 
 reagents and equipments: 
A kit provided by asserachrom vWF: Ag.(appendix) 
In addition to: 
• 1 M sulfuric acid. 
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•  Plate reader set at 450 nm. 
•  Common laboratory equipments and materials (centrifuge, vortex , stop 
watch, pipettes, distilled water..) 
 procedure: 
All the steps prescribed by the kit provider (appendix) was followed. 
The results were interpreted from the plotted curve mentioned in the test 
procedure. 
 
 
 
 
2-4 Data analysis: 
Data analyzed using Microsoft excel program (2007) for windows vista, 
and SPSS 11.01 computer program . 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 46
Chapter Three 
3. Results  
 
               This descriptive  study was conducted in Khartoum territory, in the 
period (Dec2007-Feb2008).Data was collected from patients who presented with 
menorrhagia, after being evaluated by a gynaecologist to exclude a 
gynaecological cause. Part of the data was taken from records of haemophilia 
unit in Khartoum, for patients investigated for menorrhagia as a presenting 
complaint. No previous diagnosis of bleeding disorder was known. 
• Thirty four women who fulfill the inclusion criteria were examined 
and investigated to assess their bleeding profile. Their ages 
ranged between 13 and 43 with a mean age of 25 years old, fig(3-
1). Their distribution according to age groups, showed > 70% were 
less than 30 years old.  The highest frequency38% fell within (21-
30) age group. 
• eleven women(32.5%) out of 34 women with menorrhagia,  
complained of other bleeding symptoms , mainly epistaxis. 
table(3-1) 
• Positive family history of bleeding symptoms was found in nine 
menorrhagia patients (26.6%) .table(3-2) 
• 19 women (56%) were found to have haemostatic abnormality 
(table3-3) . these were; platelet disorders (47%), vWd(32%), factor 
X deficiency(10.5%) and factor V deficiency (10.5%). table(3-4) 
• Table (3- 5): shows menorrhagia patients with other  symptoms of  
bleeding in relation  to the diagnosis of bleeding disorder. It has  a 
P value of 0.004*, which is highly significant. 
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• Table (3-6 ) correlates the diagnosis of bleeding disorder to positive 
family history of bleeding. P value of 0.447, which is statistically 
not significant. 
 
 When analyzing the laboratory data: 
• Basic screening was abnormal in 21 (62%) of the study population. 
when further evaluated; almost 90% of those who screened 
abnormal were found to have bleeding disorder; while 73% of 
those who test negative were found to be normal. These findings 
gave a p value of 0.000 which is highly significant. And sensitivity 
and specifity of the screening tests of 89.5% and 73.3% 
respectively(table3-7).  
• Prolonged bleeding time >7miutes was seen in eight patients, seven 
of them with platelet abnormality and one with VWD. Table (3-
8)and(3-9) 
• Table (3-10) and table(3-11): showed platelet count distribution and 
finger prick platelet aggregation, respectively. low platelet count 
was found in 7 patients (ref. range 150-400x109/l), 3 of them with 
defective aggregation. Two patients had very low platelet count, 
rendered their aggregation difficult to be assessed.  
• Prothrombin time with reference range of (11-14) seconds, was 
prolonged in 12 women; seven of them with mild prolongation 
having the value of 15-17 seconds. Five patient with significantly 
prolonged PT: two of them have  factor V deficiency, two with 
factor X deficiency, and one with borderline level of  factor VII  
(55%). Table(3-12) 
• Activated Partial Thromboplastin Time ref. range (23-33 seconds)  
was abnormal in nine women of the study population, four of 
them were vWd, two with factor X deficiency and two with factor 
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V deficiency, one woman showed a borderline level of vWf. 
table(3-13 ) 
• All values of prolonged PT or PTT were corrected by 50:50 mix 
with normal plasma. Further assessment was made using 
appropriate deficient plasma. 
• Thrombin Time (TT), done when both PT and PTT were prolonged, 
showed normal  values (ref range 15-19 seconds)(29)  
• Factor VIII level and vWf:ag levels were shown in table      (3-
14)and table(3-15) respectively. Their ref. range  (50-150%). Two 
patients have low level of factor VIII <50%, both of them have low 
vWf:ag level. On the other hand, 6 out of 34 patients (17.6%), have 
low level of vWf:ag and other two with borderline level. 
• Table (3-16) demonstrates the laboratory findings in the six 
menorrhagia patients with a diagnosis of von Willebrand Disease. 
• Factor XIII screening was normal for all the studied patients. 
 
 
*   Statistical analysis and cross tabulation using x2test. With level 
of significance of p value < 0.05    
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Fig( 3-1): Age distribution of the study population: 
 
The total number is 34 women. 
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Table(3-1 ):Symptoms of bleeding among the study 
population:  
  
Symptoms Frequency Percent 
Menorrhagia alone 23 67.6% 
Menorrhagia + other 
symptom of bleeding 
11 32.4% 
Total 34 100% 
 
 
 
Table(3-2 ): Family history of bleeding among patients 
with menorrhagia. 
 
Family history of 
bleeding 
Frequency Percent 
Yes  9 26.5% 
No 25 73.5% 
Total 34 100% 
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Table (3-3): The frequency of bleeding disorders among 
the study population: 
 
 
 Frequency Percentage 
Bleeding disorder 19 56% 
Normal 15 44% 
Total 34 100% 
 
 
 
 
Table(3-4): Types of bleeding disorder among women with 
menorrhagia: 
 
 
Bleeding disorder Frequency      (Percent%) 
Platelet disorders 9                     (47%) 
VWD 6                     (32%) 
Factor V deficiency 2                     (10.5%) 
Factor X deficiency 2                     (10.5%) 
Total 19                   (100%) 
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Table (3-5) : Presence of other Bleeding symptoms within  
patients in relation to the diagnosis of bleeding 
disorder: 
 
 
 
 No bleeding 
disorder 
 bleeding 
disorder 
Total 
menorrhagia alone 14 9 23 
(67.6%) 
menorrhagia 
+other symptoms  
1 10 11 
(32.4%) 
Total 15  (44%) 19   (56%) 34 (100%) 
P value: 0.004 
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Table (3-6):Family history of bleeding in relation to the 
diagnosis of bleeding disorder: 
 
 
 Bleeding disorder Total 
Yes No 
Family 
history of 
bleeding 
 Positive  6 3 9 
 Negative  13 12 25 
Total 19 15 34 
 
 
P value : 0.447 
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Table (3-7): Screening tests of haemostasis of the study 
population. 
 
 
 Screening test Total 
Abnormal Normal 
Bleeding 
disorder 
Yes 17 2 19 
56% 
No 4 11 15  
44% 
Total 21 
62% 
13 
38% 
34 
100% 
 
P value: 0.000 
Sensitivity: 89.5% 
Specifity:     73.3% 
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Table( 3-8): Bleeding time within the study population(ref. 
range2-7) (29): 
 
Bleeding time in minutes ≥ 7 minutes <7 minutes Total 
 
Frequency 
 
8    (24%) 
 
25     (76%) 
 
33  (100%) 
 
 
Table(3-9 ) Bleeding time and diagnosis of bleeding 
disorders. 
 
 Bleeding time in minutes Total 
< 7 ≥ 7 
Bleeding 
disorder 
No 14 0 14 
42% 
Yes 11 8 19  
58% 
Total 25 
76% 
8 
24% 
34 
100% 
 
P value : 0.005 
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Table(3-10 ): Platelet count groups. 
 
Platelet count 
x109/l 
Frequency Percent 
<150 7 
 
20.6% 
150-400 24 
 
70.6% 
>400 3 
 
8.8% 
Total 34 
 
100% 
 
 
 
 
Table ( 3-11 ):Finger prick platelet aggregation. 
 
Platelet aggregation Frequency Percent 
Positive 28 87.5% 
Negative 4 12.5% 
Total 32 100% 
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Table ( 3-12): Prothrombin time (PT) in seconds ( ref. range 
11-14) : 
 
PT in seconds Frequency Percent 
11-14 22 65% 
15-17 7 20% 
>17 5 15% 
Total 34 100% 
 
 
 
Table ( 3-13): Activated Partial Thromboplastin Time APTT 
in seconds (ref. range 23-33): 
 
APTT in seconds Frequency Percent 
23-33 25 73% 
34-40 4 12% 
>40 5 15% 
Total 34 100% 
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Figure (3-14 ): Factor VIII level  % in the study population, 
ref. range (50-150%): 
 
 
Factor VIII level% Frequency Percent 
<50 2 6% 
50-100 26 76.5% 
101-150 6 17.5% 
Total 34 100% 
 
 
 
 
Table (3-15 ): VWf:ag level % within the study population. 
Ref. range(50-150%): 
 
vWf:ag level % Frequency Percent 
<50 6 17.5% 
50-100 21 62% 
101-150 7 20.5% 
Total 34 100 
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Table(3-16 ): Findings in patients with vWd: 
 
Patient 
No. 
Age 
Years 
Bleeding 
Time(min) 
aPTT 
(control 28-
30 sec.) 
vWf:ag 
level 
% 
Factor 
VIII 
level% 
Family 
history  
1 20 4 39 42 52 No 
2 43 3 36 42 65 No 
3 13 3 26 24 65 No 
4 23 4 37 22 44 No 
5 13 4 32 8 85 No 
6 20 14 56 1 11 Yes 
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Chapter Four 
 
Discussion 
 
 
            Menorrhagia is a common gynaecological symptom, a specific cause is 
identified in less than 50% of affected women, it may be a manifestation of an 
underlying inherited disorder of coagulation. Kadir etal(15) found that: 73% of 
women with Von Willebrand Disease, 57% of women who are carriers of 
Hemophilia A or B and 59% of women with Factor XI Deficiency suffer from 
menorrhagia.  
           This study was designed to assess the prevalence of bleeding disorders 
among women presenting with menorrhagia in Khartoum hospital. 
           Thirty four women in the reproductive age, were included In this study. 
They had a diagnosis of menorrhagia , with no gynaecological cause identified. 
Their ages ranged between 13- 43 years old; most of them were adolescents and 
young adults. 
          When they were investigated for haemostatic abnormality; nineteen of 
them (56%) were found to have bleeding disorders; including  platelet 
disorders(47%); vWd (32%); coagulation factors deficiencies; factor X 10.5%and 
factor V 10.5%. 
     A similar study was done in Gorgia ; forty seven percent of women with 
menorrhagia were found to have bleeding disorders.( 21) Mitchel L. Zoler, 
reported in a study of 30 patients at one institution in  Philadelphia, that about 
half of adolescents with menorrhagia have an underlying bleeding disorder.(31) 
Another study done by Kadir RA etal, revealed a frequency of bleeding disorders 
of 17% of which13% were vWd and 4% Factor XI deficiency, platelet disorders 
were not fully evaluated(15 ). 120 women from western India aged between 18 and 
 61
35 years presenting with menorrhagia without any obvious cause were studied 
for bleeding disorders. 19.16% (23 cases) had an inherited coagulation disorder. 
The majority (11.6%) were patients with von Willebrand s disease (vWD), rare 
platelet disorders such as Glanzmann s thrombasthenia (3.3%), Bernard-Soulier 
syndrome (0.83%), coagulation factor deficiencies such as factor VIII (0.83%), 
factor X (0.83%), and factor XI (0.83%), and immune thrombocytopenia (0.83%) 
were also found.(32)   
   Data from another Indian study reported that , there were 337 women having 
inherited bleeding disorder from 2200 women with menorrhagia. Platelet 
abnormalities were the most prevalent disorders,86%; followed by vWd,11.9%.(33) 
       There is evidently a wide variation in the prevalence of bleeding disorders 
among patients presenting with menorrhagia within different studied groups. 
This in part can be explained by different designs used to study these 
abnormalities or due to difference in methods used for their investigation. 
Noteworthy that, the epidemiology of bleeding disorders itself is widely 
variable. Some studies found a substantial difference in vWd prevalence among 
white and black Americans , as well as platelet abnormalities; they found that for 
unknown reason, African American women have higher levels of vWf and factor 
VIII. Platelet disorders is more common in black American.(14,15,18) Other rare 
autosomal recessive hereditary coagulation disorders exhibit similar variation, 
they are found to be relatively more common in Muslim countries and parts of 
India and middle east, this was due to the increased frequency of 
consanguineous marriages within these communities.  Moreover, some 
hereditary disorders were shown to be clustered within specific groups e.g. 
factor XI deficiency in Ashkenazi Jews(24).  
           No similar studies were done in our country or even a comparable group 
of people, so we cannot assess the compatibility of these findings. 
            A history of bleeding symptoms other than menorrhagia, mainly epistaxis, 
was a significant finding in this study. It might be used as a predictor of presence 
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of bleeding disorder. This finding is supported by the west Indian study(32), 
which reported that; history of bleeding from other sites howsoever minor, 
paternal consanguinity as well as family history of bleeding tendencies appeared 
as a very strong predictor for such kinds of disease in patients with 
menorrhagia.(32)  
           Nine women of the study population had family history of bleeding, six of 
them were found to have bleeding disorder while the remaining three showed 
no haemostatic abnormality, these 6 patients demonstrates one third of patients 
with bleeding disorders. On the other hand about half the patients with no 
family history of bleeding had abnormal haemostasis. These findings  were 
proved not to be significant statistically (table3-6), hence they can support the 
possibility of bleeding disorder but cannot be used as a predictor of their 
presence. In contradistinction to what mentioned in the west Indian study(32 ), 
and to another study by Yasmin, which found that The only statistically 
significant predictor was a family history of bruising and bleeding among 
teenagers presenting with menorrhagia(34) . Family history specially for excessive 
menstrual bleeding is difficult to assess. Often, women themselves did not 
realize they were not normal. Their bleeding problem ran in the family. 
Therefore sisters, mothers, grandmothers, and aunts often had the same problem. 
Nobody saw it as special or, if they did, they said, "All the women in our family 
bleed a lot during their periods.(14,16 ) 
        The pattern of inheritance of bleeding disorders is also variable, that most of 
the hereditary disorders are autosomal recessive, and even the autosomal 
dominant ,like vWd, has different penetrance(24,35). 
        Most of the patients with  inherited coagulation defects were adolescent and 
young adults, indicating their severity. All the four patient with factor V and X 
deficiency reported presence of other symptoms of bleeding, and their 
menorrhagia commenced with menarche. The later finding was not available for 
all the study population, hence its significance was not assessed. Patients with 
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mild symptoms do not present early to seek medical advice, nevertheless, 
bleeding disorders themselves have very variable clinical presentation, patients 
might suffer no, or very minor symptoms and only bleed during major challenge 
like surgery or child birth.(35) 
         Screening tests used in this study were found to be more sensitive than 
specific, this is consistent with what mentioned in the literature.(29,35)Although its 
sensitivity could have been better if more evaluation was done for the positive 
findings. For example patients with prolonged aPTT and borderline levels of 
vWf could have lower levels of vWf if the test was repeated in different occasion. 
        Of the 33 women tested for their bleeding time; eight women had prolonged 
bleeding time and all of them had a bleeding disorder (p value 0.005). Seven of 
them had platelet disorder and only one with vWd. Bleeding time is 
controversial as a screening test, it has no predictable pattern; it is best viewed as 
being sensitive but not specific(35). There are different methods for its 
determination, standardization of these test procedures is not easily feasible. 
Recently, platelet function analyser PFA-100, is getting acceptance as a preferred 
method to determine  bleeding time. The PFA-100 measures the time it takes for 
a specimen of citrated whole blood in a capillary tube to block a membrane by 
forming a platelet plug, a parameter known as the closure time. Closure time is a 
measure of platelet aggregation and adhesion.(31)A recent study in Philadelphia;  
which included 30 girls aged 11-16 years (mean age was 13); who were referred 
for assessment following a clinical diagnosis of menorrhagia; stated that; it was a 
good way to assess bleeding disorders in these young patients with a platelet 
function analyzer, such as the PFA-100, Dr. Victoria J. Davis said during the 
annual meeting of the North American Society for Pediatric and Adolescent 
Gynecology:"I would use this test instead of bleeding time measurements to 
screen patients for a bleeding disorder. We are confident that two sequential, 
positive results using the platelet function analyser identify patients who have a 
platelet-function or clotting disorder," she concluded(31).  
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            Table(3-10) demonstrated that platelet count was low in seven patients, 
two of them showed abnormal aggregation by finger prick method, they might 
have Bernard Soulier disorder if evaluated further. Three patients with mild 
elevation of platelet count, with values less than 600x109/l, could have for 
example iron deficiency which is common finding in such patients, or they might 
have ongoing bleeding. 
         Finger prick platelet aggregation was defective in four patients, this is a 
crude simple test which is unable to define the exact abnormality of platelet 
function..   
        PT (table3-12 ) the reference range was 11-14 seconds according to the kit 
used, PT was mildly prolonged in 7  patients having the value of 15 seconds, 
these were not regarded as significant abnormalities and no further 
investigations were performed. PT was significantly prolonged >17 seconds in 
five women ; two of them with factor V deficiency, two with factor X deficiency, 
with very prolonged PT, and one with borderline  factor VII level (55%). Factor 
VII deficiency is associated with severe bleeding including a high frequency of 
intracranial haemorrhage. Oddly, some patients with very low levels do not 
manifest bleeding, and even thrombosis has been reported(35). This patient with 
isolated prolongation of PT and significant bleeding history and family history, 
needs further evaluation. 
PT is an easy test with end point easy to be determined and clear cut results. 
Standardization of its result can be achieved by using International 
Normalization Ratio (INR) rather than measured values.(29,35) 
            Using a normal range for APTT (23 -33)seconds, table(3-13), it  was found 
to be abnormal in nine menorrhagia patients; four of them had low levels of vWf, 
two with factor X and two with factor V deficiencies. another woman with 
mildly prolonged APTT had  borderline vWf levels, the possibility of vWd 
variants cannot be excluded, since no functional assay was performed. Still type I 
vWd could be suspected, because in this study the time of sampling was not 
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related to specific time in the menstrual cycle . vWf is an acute phase reactant, its 
level is affected by estrogen and many other factors which can cause higher 
levels leading to difficulty in diagnosing vWd( 19). The severity of bleeding was 
not assessed, as it is not included in the design of this study.  
          Most of the patients had factor VIII and vWf:ag levels between 50-
100%.tables (3-14, 3-15). This necessitates the establishment of local reference 
ranges. For proper interpretation of results. 
            Table (3-16) which demonstrates the laboratory findings in the six women 
with vWd, shows a prolonged bleeding time in only one patient. it is known that 
the bleeding time could be prolonged or normal in vWd, still the procedure used 
in this study has an inherent error, may be different results would have been 
obtained if another sensitive method was used.  
              Another finding is the normal or mildly prolonged aPTT in vWd patients 
which is not an uncommon finding , adding to the difficulties in diagnosing  
vWd, which can be easily missed by routine screening tests.(19 )Most patients 
were adolescents and young adults, only one old lady was diagnosed, adding to 
what mentioned earlier about delayed diagnosis of many patients with bleeding 
disorders.(15) VWf:ag was almost absent as well as factor VIII which was 
markedly reduced in only one patient, who could be classified as type 3 vWd. 
This was the only patient with vWd who had very prolonged bleeding time and 
positive family history of bleeding, indicating severe disease. Another patient 
with low vWf:ag (8%), strangely had normal factor VIII level 85%, which needs 
more evaluation. The rest of vWd patients seemed to be type 1 which is the 
commonest type. All of these vWd patients had normal platelet count excluding 
vWd variants associated with abnormal platelet count. Two patients with 
borderline vWf:ag level, one of them had mildly prolonged aPTT the other had  a 
normal aPTT. They were discussed earlier. 
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Difficulties faced in this study: 
 
• No previous data about menorrhagia and bleeding disorders in Sudan to 
build on it , and to assist in the design of this study.  
 
• The study population were cooperative during the initial interview. But 
when tried to contact them for more sampling for confirmation of the 
initial findings, they were reluctant. 
 
• The samples had to be processed within short time in a laboratory distant 
from the collection site, hence very few samples to be taken per day. 
 
• The reliability of inclusion of individuals was not assessed by the study 
design, it depended on a gynaecologist evaluation, who might face the 
difficulties of the definition of menorrhagia itself and the assessment of 
the amount of bleeding. 
 
• The requirements for performing all the laboratory testing were not 
available in a single place. 
 
• No local reference ranges available for proper interpretation of laboratory 
results. 
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Chapter Five 
 
 
 
 
Conclusions and recommendations 
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Conclusions 
 
 
• Haemostatic abnormalities  were found to be prevalent among 
patients presented with menorrhagia in this study. 
 
• Platelet abnormalities were the most common bleeding disorders 
causing menorrhagia among the study population; followed by 
vWd. 
 
• Other rare coagulation factors deficiencies , can also manifest as 
menorrhagia. They were found to be prevalent among the study 
population. 
 
 
• Simple screening tests, although somewhat sensitive, still can miss 
some cases of bleeding disorders. Especially vWd which can evade 
diagnosis by routine testing. 
 
• Still the design of this study did not cover all aspects of 
haemostasis, e.g. fibrinolysis,  so their presence cannot be excluded 
 
• Presence of other symptoms of bleeding might  be used as a 
predictor of the presence of bleeding disorder. 
 
• Family history of bleeding was not a predictor of the presence of 
bleeding disorders as a cause of menorrhagia. However it might 
support its presence 
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Recommendations 
 
 
• Haemostatic disorders should be suspected whenever  there is  
significant bleeding symptoms in patients with menorrhagia 
without an obvious cause. They should be investigated within a 
reliable laboratory, for proper management and before  
performing any invasive procedure. 
•  Specialized, reliable laboratory should be available, to limit the 
variability of test results , and to perform further testing when 
screening tests are abnormal. 
• vWd should have special consideration in patients with 
menorrhagia , since it can be missed by routine testing. 
• A bigger well controlled study should be performed to find out 
the actual prevalence of bleeding disorders in the general 
population in Sudan as well as among patients with 
gynaecological bleeding including menorrhagia. 
• There should be a joint clinic or referral system, for collaborate 
evaluation of  gynaecological bleeding and menorrhagia in 
particular, and for sharing opinion between haematologists and 
gynaecologists, so as to alleviate the suffering of patients, 
wondering without a diagnosis for a long time.   
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                             Appendix 1 
 
Questionnaire 
 
 
Number                                 contact no…………………………… 
 
Name: …………………………………… 
 
Age: 
 
tribe:………………………..                                                             
 
residence:…………………… 
 
marital status:……………           single :               married:     
 
Menarche:…………. 
 
Katamena:…………………. 
     
 
Duration of menorrhagia: ………………………                            
 
History of bleeding from other sites:  yes             No                
 
 
Drug history:  
  
          NSAID within 2 weeks:……yes                No 
 
                   
 
          Hormonal therapy:……………yes                      No 
                      
Family history of bleeding:…………yes                 No  
 
.............................................................................................. 
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Investigations: 
 
 
 
1. Bleeding time:………………………. 
2. Platelet count:……………………………… 
3. Finger prick platelet aggregation:…………………………. 
4. PT:………………………………………………. 
5. aPTT:………………………………………… 
6. F VIII level:…………………………………. 
7. VWF level:…………………………………. 
8. F XIII assay:…………………………….. 
9. Other factors:…………………………… 
 
 
 
 
